723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models

• Christopher Nirschl,
• Kristin Morris,
• Heather Brodkin,
• Nesreen Ismail,
• Andres Salmeron,
• Philipp Steiner,
• Zoe Steuert,
• Jenna Sullivan,
• William Winston,
• Cindy Seidel-Dugan,
• Ethika Tyagi,
• Josue Canales,
• Dan Hicklin

Affiliations

Christopher Nirschl

Aff1 grid.38142.3c000000041936754XBrigham and Women`s Hospital, Department of DermatologyHarvard Medical School Boston MA USA

Kristin Morris

1Werewolf Therapeutics, Cambridge, MA, United States

Heather Brodkin

1Werewolf Therapeutics, Cambridge, MA, United States

Nesreen Ismail

1Werewolf Therapeutics, Cambridge, MA, United States

Andres Salmeron

1Werewolf Therapeutics, Cambridge, MA, United States

Philipp Steiner

1Werewolf Therapeutics, Cambridge, MA, United States

Zoe Steuert

1Werewolf Therapeutics, Cambridge, MA, United States

Jenna Sullivan

2Werewolftx.com, Cambridge, MA, United States

William Winston

1Werewolf Therapeutics, Cambridge, MA, United States

Cindy Seidel-Dugan

Werewolf Therapeutics, Cambridge, MA, United States

Ethika Tyagi

Werewolf Therapeutics, Cambridge, MA, United States

Josue Canales

Werewolf Therapeutics, Cambridge, MA, United States

Dan Hicklin

Werewolf Therapeutics, Cambridge, MA, United States